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Metabolic and morphological side-effects occur in HIV-infected individuals receiving anti-retroviral treatment
(ART). Peripheral fat loss that occurs particularly in the face, limbs and/or buttocks is referred to as
lipoatrophy and has been found to be highly stigmatizing and to adversely impact the health-related quality
of life (HRQL). Consumer Health Sciences Survey data collected between November 2003 and January 2006
were utilized to evaluate the impact of lipoatrophy on the HRQL in HIV-infected individuals receiving ART.
This was evaluated using analysis of variance with item scores and mental component summary (MCS) and
physical component summary (PCS) scores from the Medical Outcomes Trust questionnaire, SF-8 as
dependent variables and lipoatrophy as the independent variable controlling for baseline age, sex and
ethnicity. Clinical meaningfulness (mean difference divided by population standard deviation, d/s) of
differences between the groups with and without lipoatrophy was also evaluated. A cohort of 1124 subjects
with at least six months of ART was selected based on the availability of data on whether or not lipoatrophy
was present. Subjects were primarily male (80%), between the ages of 30 and 60 years (90%), Hispanic (37%)
and about 25% each of African American and White. Overall, prevalence of lipoatrophy in this cohort of
HIV patients was 18.9%. Statistically significant (pB0.001) differences in quality of life (as measured by SF-8
individual item scores and MCS and PCS scores) were observed between the two groups. The differences
between the groups in item and summary scores were clinically meaningful in the small to near medium range
(0.280.43). HIV-infected patients already experience a considerable deficiency in HRQL compared to general
population; this study demonstrates that lipoatrophy further enhances that negative impact on HRQL.
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Introduction
Metabolic and morphological side-effects occur in
HIV-1 infected individuals receiving anti-retroviral
treatment (ART) (Moyle, Brown, Lysakova, Barton,
et al., 2006). Peripheral fat loss, particularly occurring
in the face, limbs and/or buttocks, is also known as
lipoatrophy. In a Swiss HIV cohort study, the
prevalence of abnormal body fat distribution in
HIV-treated individuals was assessed (Bernasconi et
al., 2002) and fat loss in the face, leg(s), arm(s) and/or
buttock(s) was reported by 28% of the study subjects.
Santos, Felipe, Braga, Ramos, Lima, et al. (2005),
from Brazil, interviewed a total of 457 patients in a
university outpatient facility for the treatment of
adults and adolescents with HIV/AIDS in the city of
Sao Paulo, Brazil, between September and December
2001. They reported about 37% of self-perceived
peripheral fat loss. In ACTG study 5142 (ACTG,
2007), where a protease inhibitor (PI)-sparing group,
a non-nucleoside reverse transcriptase inhibitor
(NNRTI)-sparing group and a nucleoside/nucleotide
reverse transcriptase inhibitor (NRTI)-sparing group
were compared, lipoatrophy was diagnosed by Dual-
X-Ray Absorptiometry (DEXA) and greater than
20% loss of extremity fat was considered lipoatrophy.
Incidence of lipoatrophy was 32% in the PI-sparing
group, 17% in the NNRTI-sparing group and 9% in
the NRTI-sparing group.
HIV-infected individuals with no report of lipoa-
trophy experience HRQL reductions commensurate
with disease severity (Table 1) (Revicki, Sorenson,
Wu, et al., 1998; Ware et al., 2001). Lipoatrophy
results in noticeable weight loss in the extremities and
reductions in physical and mental strength and
vitality and can be highly stigmatizing (Bernasconi,
Boubaker, Junghans, Flepp, Furrer, et al., 2002; Tien
& Grunfeld, 2004). Patients with lipoatrophy face the
potential of worsening fat redistribution with con-
tinued therapy or the possibility of worsening vir-
ologic control and disease progression with a change
in therapy (Lenert & Feddersen, 2002). The combina-
tion of negative effects on physical and mental
function and self-esteem may have a further adverse
impact on HRQL, attitude towards treatments and
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Antinori, Cozzi-Lepri, Trotta, Nasti et al., 2002;
Guaraldi, Murri, Orlando, Orlandi, Sterrantino et
al., 2003; Power, Tate, McGill & Taylor, 2003;
Reynolds, Neidig, Wu, Gifford & Holmes, 2006).
The objective of this data analysis was to evaluate
the impact of lipoatrophy on the health-related
quality of life in HIV-infected individuals receiving
ART using the Consumer Health Sciences (CHS)
Survey data collected between November 2003 and
January 2006.
Methods
Survey database
Consumer Health Sciences survey data are marketed
to any pharmaceutical company interested in pur-
chasing the survey data. The pharmaceutical compa-
nies may or may not have a product in the market/
development. Various pharmaceutical companies
provide funding for this questionnaire, but by no
means do CHS promote any products.
The questionnaire does not necessarily target any
particular side-effect for the HIV cohort. The HIV-
infected individuals are asked to check off whatever
conditions they have, either as co-morbidities or as
side-effects, from the exhaustive list on the survey. In
addition, they are all administered the SF-8 Medical
Outcomes Trust questionnaire to evaluate their
health-related quality of life. Consumer Health
Sciences recruited HIV patients from both commu-
nity-based centers and clinics for uninsured persons
and also using advertisement in newspapers and
websites via Lightspeed Research panel of US
customers. Recruiters contacted the centers and
asked them to participate in the survey activities.
They were then sent a pack of materials required for
the project. The centers would be paid per completed
questionnaire returned to CHS and respondents
would also be paid an incentive for their participa-
tion. Multiple-source methodology removes the in-
herent bias of using too few sources and enhances the
quality of the panel. The goal for CHS was to have a
nationally representative view of the HIV/AIDS
marketplace.
Given that the database for Wave 1 was not
readily available in addition to the time limitations of
the project, only Waves 2 and 3 were utilized.
The response data were managed by the CHS,
Inc. and were licensed out for research purposes.
Survey data were collected in two waves as follows:
. Wave 2: Survey packages were distributed to
HIV-infected individuals in 257 community
centers/clinics and interested HIV-infected
individuals completed the surveys, which
were returned to CHS: n1024; data col-
lected from November 2003 through Febru-
ary 2005.
. Wave 3: In addition to the above method, in-
person (self-administered) interviews and In-
ternet interviews were used with HIV-infected
individuals: n1001; data collected from Oc-
tober 2005 through January 2006 (Table 2).
The number of individuals to whom the survey was
distributed in the community centers/clinics was not
documented. However, it is apparent that the in-
dividuals’ decision-making process to respond was
highly unlikely to be influenced by the presence or
absence of lipoatrophy. We are certain that this bias
Table 1. Comparison of SF-8 Norms for the general US population with those for HIV-infected individuals.
Norm for US general population
(n7472)*
Scores for HIV-infected individuals
(n871)**
SF-8 item Mean SD*** Mean
Physical functioning (PF) 48.27 7.75 43.87
Role physical (RP) 48.59 7.83 43.48
Bodily pain (BP) 50.00 8.58 45.87
General health (GH) 49.44 7.45 46.75
Vitality (VT) 50.06 7.82 46.65
Social function (SF) 48.54 8.21 42.81
Role emotion (RE) 47.04 7.18 41.90
Mental health (MH) 48.97 8.77 41.40
Notes: *Data ‘‘Norm for US general population’’ are from the MOS scoring manual.
**Data for the HIV-infected individuals (with no lipoatrophy reported) are from CHS survey. N for the 8 items ranged from 859871.
***Using this standard deviation (SD), the clinically meaningful difference between the groups (Cohen’s effect size) for each item ranges from
medium to large.
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contained an exhaustive list of items pertaining to
HIV/AIDS (lipoatrophy was only one among them);
and (2) the prevalence of lipoatrophy (18.9%) in our
cohort is consistent with the range we found in the
literature.
Eligibility criteria
Patients must have used an HIV prescription pro-
duct for at least six months and have non-missing
data for each of the covariates of interest (SF-8,
lipoatrophy [occurrence of both weight loss and
facial atrophy as reported by patients], age, gender
and ethnicity). The total number of patients included
in the analysis1124. The remaining 901 individuals
who did not meet the criteria were excluded from the
analysis.
Statistical analysis
The impact of lipoatrophy was evaluated using linear
regression with: (1) each item score; (2) MCS; and (3)
PCS scores from the Medical Outcomes Trust ques-
tionnaire, SF-8 as dependent variables. Lipoatrophy
(based on the participant response of either ‘yes’ or
‘no’ to the survey question) was the primary inde-
pendent variable controlling for baseline age, sex and
ethnicity as covariates. All tests are two-sided with a
significance level below 0.05.
Clinically meaningful effect measured as mean
difference between the groups with and without
lipoatrophy divided by population standard deviation
(d/s) was also evaluated. This effect size is graded as
small (]0.2 andB0.5), medium (]0.5 andB0.8)
and large (]0.8) (Cohen, 1988).
Results
A cohort of 1124 subjects met the selection criteria.
Demographic data are shown in Table 3.
Overall, the prevalence of lipoatrophy was 18.9%.
Statistically significant (pB0.001) differences in
HRQL (as measured by SF-8 individual item scores
and MCS and CS scores) were observed between the
two groups (Table 4). The differences between the
groups in item and summary scores were clinically
meaningful with Cohen’s effect size in the small to
near medium range (0.26 to 0.43).
Prevalence of lipoatrophy regardless of weight
loss was 30.2% in this same cohort. In this secondary
analysis, also, statistically significant (pB0.001) dif-
ferences in health-related quality of life (as measured
by SF-8 individual item scores, MCS and PCS scores)
were observed between the two groups. The clinically
meaningful differences (Cohen’s effect size) between
the groups in item and summary scores ranged from
0.160.33 (data not shown).
Discussion
In this study, lipoatrophy was associated with a
negative impact on the HRQL in HIV-infected
individuals. Data used for this analysis were ex-
tracted from the CHS survey responses, which were
voluntarily provided by a cohort of self-selected
HIV-infected individuals. Whether the subjects that
responded to surveys of this sort reflect the general
population of HIV-infected individuals is not certain.
Therefore, caution is essential in generalization of
these data across diverse demographical groups.
However, with regard to lipoatrophy, the prevalence
of 18.9% is consistent with the prevalence of
lipoatrophy found in other published data (ACTG
2007; Bernasconi, Boubaker, Junghans, Flepp,
Furrer et al., 2002; Santos, Felipe, Braga, Ramos,
Lima et al., 2005). Again, it should be noted that
individual’s self-perception was the sole support for
the data. Structured research studies use objective
evaluations to diagnose lipoatrophy and they vary in
the criteria they use (for example, the ACTG study
considered a patient to have lipoatrophy only if at
least 20% of atrophy was demonstrated by DEXA
(ACTG, 2007). Researchers have demonstrated that
NRTItherapy is associated with mitochondrial
DNA depletion and cell death, explaining the high
end of incidence rate in the PI-sparing group of the
ACTG study (Mauss, Corzillius, Wolf, Schwenk,
Adam et al., 2002; Nolan, Hammond, Martin,
Table 2. Data collected during the period from 11/03 to 01/06.
Source: Wave and site Distributed/ attempted Completed n (%)
Wave 2 Community Center/clinic NA 1024 (NA)
Wave 3 Community Center/clinic NA 313 (NA)
Wave 3 In-person interviews 261 237 (91)
Wave 3 Internet interviews 550 451 (82)
Total NA 2025
AIDS Care 1199Taylor, Herrmann et al., 2003, Powderly, 2003; Sax
& Gathe, 2005). In the ACTG-5142 study, subjects
who received Efavirenz (EFV) in combination with
NRTIs had significantly higher rates of lipoatrophy
than subjects who received lopinavir/ritonavir in
combination with NRTIs, not including the Tenofo-
vir combinations (ACTG, 2007).
When patients report self-perceived fat loss in
face, limbs and buttocks, they also report its negative
impact on HRQL, particularly self-esteem, social
Table 3. Demographic characteristics of the study cohort of HIV-infected individuals.
Lipoatrophy
Lipoatrophy and demographic variables Overall Yes No p-value*
Self-report of lipoatrophy (n) 1124 212 912
Age group n212 n912 ns
2029 4.9 7.6 4.3
3039 24.3 22.2 24.8
4049 43.6 43.9 43.5
5059 21.6 21.2 21.7
6069 4.3 3.3 4.5
70  1.3 1.9 1.2
Ethnicity n204 n891 B0.0001
African American 28.1 16.7 30.8
American Indian 2.9 8.8 1.6
Asian 6.4 6.9 6.3
Hispanic 37.6 36.3 37.9
White 24.9 31.4 23.5
Gender n209 n900 ns
Female 21.3 19.6 21.7
Male 78.7 80.4 78.3
Employment status n199 n839 ns
Full time 26.7 26.1 26.8
Part time 9.8 8.5 10.1
Homemaker 2.7 5.5 2
Retired 4.9 3.5 5.2
Unemployed 10.8 8.5 11.3
Disabled 44.9 47.7 44.2
No answer 0.2 0 0.2
Notes: *p-value based on Pearson Chi-square test for each demographic variable.
Table 4. Effect of lipoatrophy on SF-8. Summary scores and item scores.
Lipoatrophy
SF-8 variables n Yes n no p-value Diff Total pop. SD CMD*
Physical component summary (PCS) 190 40.58 832 45.17 B0.0001 4.585 10.626 0.431
Mental component summary (MCS) 190 37.83 832 41.54 0.0001 3.714 11.973 0.310
Daily activities (RE) 195 38.23 862 41.90 B0.0001 3.666 8.909 0.412
Emotional affect (MH) 198 38.56 866 41.40 0.0011 2.838 10.974 0.259
Energy (VT) 199 44.04 867 46.65 0.0004 2.612 9.205 0.284
General health (GH) 199 43.54 871 46.75 B0.0001 3.213 8.565 0.375
Pain (BP) 199 42.20 859 45.87 B0.0001 3.674 10.334 0.356
Physical problems (PF) 197 39.94 867 43.87 B0.0001 3.936 9.250 0.426
Social (SF) 198 38.63 861 42.81 B0.0001 4.172 9.948 0.419
Work (RP) 197 39.30 866 43.48 B0.0001 4.181 10.064 0.415
Notes: *CMDClinically meaningful differences. Patients with lipoatrophy had worse HRQL in both summary scores and in all eight
individual questions, with the clinically meaningful differences ranging from 0.2590.431 (small to medium)
1200 R. Rajagopalan et al.contacts, sexuality and daily activities (Bernasconi,
Boubaker, Junghans, Flepp, Furrer et al., 2002;
Mauss, Corzillius, Wolf, Schwenk, Adam et al.,
2002; Nolan, Hammond, Martin, Taylor, Herrmann
et al., 2003; Powderly, 2003). The CHS data reflect
similar findings that lipoatrophy contributes substan-
tially to reductions in HRQL.
Conclusion
HIV-infected individuals experience a considerable
reduction in health-related quality of life compared to
the general population. The current analysis demon-
strates that further significant reductions in HRQL
occur in HIV-infected individuals who also report
lipoatrophy.
Note
1. Presented at the 9th International Workshop on Adverse
Drug Reactions and Lipodystrophy in HIV, Sydney,
Australia, July 1820, 2007
References
ACTG. (2007). Metabolic outcomes of ACTG 5142: A
prospective, randomized Phase III trial of NRTI-, PI-
and NNRTI-sparing Regimens for initial treatment of
HIV-1. Presented at the 14th Conference on Retrivirus
and Opportunistic Infections, February 2528, Los
Angeles, CA.
Ammassari, A., Antinori, A., Cozzi-Lepri, A., Trotta,
M.P., Nasti, G., Ridolfo, A.L., et al. (2002). Relation-
ship between HAART adherence and adipose tissue
alterations. Journal of Acquired Immune Deﬁciency
Sundrome, 31(Suppl. 3), S140S144.
Bernasconi, E., Boubaker, K., Junghans, C., Flepp, M.,
Furrer, H.J., Haensel, A., et al. (2002). Abnormalities
of body fat distribution in HIV-infected persons
treated with antiretroviral drugs: The Swiss HIV
cohort study. Journal Acquired Immune Deﬁciency
Syndrome, 31,5 0 55.
Cohen, J. (1988). Statistical power analysis for the beha-
vioral sciences (2nd ed) (pp. 2027). Hillsdale, NJ:
Lawrence Eribaum.
Guaraldi, G., Murri, R., Orlando, G., Orlandi, E.,
Sterrantino, G., Borderi, M., et al. (2003). Morpholo-
gic alterations in HIV-infected people with lipodystro-
phy are associated with good adherence to HAART.
HIV Clinical Trials, 4,9 9 106.
Lenert, L.A., & Feddersen, M. (2002). Adverse effects of
medications and trade-offs between length of life and
quality of life in human immunodeﬁciency virus
infection. American Journal of Medicine, 113, 229232.
Mauss, S., Corzillius, M., Wolf, E., Schwenk, A., Adam,
A., Jaeger, H., et al. (for the DAGNA ¨ Lipantiretro-
viral therapy study group). (2002). Risk factors for the
HIV-associated lipodystrophy syndrome in a closed
cohort of patients after three years of antiretroviral
treatment. HIV Medicine, 3,4 9 55.
Moyle, G.J., Brown, S., Lysakova, L., & Barton, S.E.
(2006). A randomized comparative trial of tenofovir
DF or abacavir as replacement for a thymidine
analogue in persons with lipoatrophy. AIDS, 20,
20432050.
Nolan, D., Hammond, E., Martin, A., Taylor, L.,
Herrmann, S., McKinnon, E., et al. (2003). Mitochon-
drial DNA depletion and morphologic changes in
adipocytes associated with nucleoside reverse tran-
scriptase inhibitor therapy. AIDS, 17, 13291338.
Powderly, W.G. (2003). Limitations in HIV therapies:
Opportunities for improvement. Journal of AIDS, 33,
S7S16.
Power, R., Tate, H.L., McGill, S.M., & Taylor, C. (2003).
A qualitative study of the psychosocial implications of
lipodystrohy syndrome on HIV-positive individuals.
Sexually Transmitted Infections, 79, 137141.
Revicki, D.A., Sorensen, S., & Wu, A.W. (1998). Reliability
and validity of physical and mental health summary
scores from the Medical Outcomes Study HIV Health
Survey. Medical Care, 36(2), 126137.
Reynolds, N.R., Neidig, J.L., Wu, A.W., Gifford, A.L.,
Holmes, W.C., et al. (2006). Balancing disﬁgurement
and fear of disease progression: Patient perceptions of
HIV body fat redistribution. AIDS Care, 18(7), 663
673.
Santos, C.P., Felipe, Y.X., Braga, P.E., Ramos, D., Lima,
R.O., & Segurado, A.C. (2005). Self-perception of
body changes in persons living with HIV/AIDS:
Prevalence and associated factors. AIDS, 19 (Suppl.
4), S1421.
Sax, P.E., & Gathe, J.C., Jr. (2005). Beyond efﬁcacy:
Impact of combination antiretroviral therapy on
quality of life. AIDS Patient Care and STDs, 19(9),
563576.
Tien, P.C., & Grunfeld, C. (2004). What is HIV-associated
lipodystrophy? Deﬁning fat distribution changes in
HIV infection. Current Opinion in Infectious Diseases,
17,2 7 32.
Ware, J.E., Jr., & Kisinski, M., Dewey, J.E. & Gandek, B.
(2001). How to score and interpret Single-Item Health
Status Measures. A manual for users of the SF-8
TM
Health Survey. Lincoln, RI: QualityMetric.
AIDS Care 1201